Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
July 22, 2025Clinical and Experimental MedicineOpen Access

Efficacy and safety of doxycycline for severe Mycoplasma pneumoniae pneumonia in pediatric patients

View Full Paper
Ask AI
Bookmark
Share

Authors

QZQian ZhaoXSXu SangDGDing Gao

Discussion

Loading...

Member takes

Overview

Clinical analysis shows doxycycline improves pneumonia outcomes in children, indicating its efficacy and safety over macrolides.

Key Points

  • Doxycycline treatment led to shorter cough relief time (5.4 days) compared to macrolides (7.2 days), indicating better efficacy.
  • The treatment efficacy rate for doxycycline was 88.6%, while that for macrolides was 75.0%, showing a significant difference.
  • No notable differences were found in fever resolution time or hospitalization duration between the treatment groups.
  • Safety analysis indicated similar adverse event rates, primarily mild, emphasizing doxycycline's safety in pediatric use.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/689a061be6551bb0af8cd81chttps://doi.org/10.1007/s10238-025-01793-x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Macrolide-Resistant Mycoplasma pneumoniae Infection Successfully Treated With Doxycycline and Immunomodulators in a Pediatric Patient: A Case Report2025
  2. 2Comparison Of Inflammatory Control And Safety By Timing Of Doxycycline-Azithromycin Dual Therapy In Pediatric Mycoplasmal Pneumonia2025
  3. 3Efficacy of systemic glucocorticoids in pediatric Mycoplasma pneumoniae infection2025
  4. 4Efficacy and safety of nebulized drugs in the treatment of non-severe mycoplasma pneumoniae pneumonia in children - a network meta-analysis2025
  5. 5Clinical efficacy of azithromycin-budesonide combination therapy in pediatric Mycoplasma pneumoniae pneumonia2025